$441.01 -5.5 -1.2%
Last Trade - 02/03/21
| Market Cap | £46.79bn |
| Enterprise Value | £45.15bn |
| Revenue | £2.33bn |
| Position in Universe | 184th / 6633 |
| Industry | Market | |
|---|---|---|
|
|
|
|
|
|
|
|
|
|
|
| Year End 03rd Jan | 2015 | 2016 | 2017 | 2018 | 2019 | 2020 | 2021E | 2022E | CAGR / Avg | |
|---|---|---|---|---|---|---|---|---|---|---|
| 2,220 | 2,398 | 2,752 | 3,333 | 3,543 | 3,239 | 3,898 | 4,513 | +7.9% | ||
| +56.2 | -2.1 | +95.9 | -7.0 | +14.0 | -30.8 | +37.9 | +24.6 | |||
|
x
|
||||||||||
| Profitability | ||||||||||
|
%
|
||||||||||
|
%
|
||||||||||
|
%
|
||||||||||
| Cashflow | ||||||||||
| Dividends | ||||||||||
| Balance Sheet | ||||||||||
|
m
|
||||||||||
|
m
|
||||||||||
|
m
|
||||||||||
| Leverage (ttm) | Total | - Intang | + Pension |
|---|---|---|---|
| Gross Gearing % | |||
| Net Gearing % | |||
| Cash / Assets % |
| Liquidity (ttm) | ||
|---|---|---|
| Curr. Ratio | ||
| Quick Ratio | ||
| Interest Cov. | ||
| Efficiency (ttm) | ||
|---|---|---|
| Asset Turnover | ||
| Recs Turnover | ||
| Stock Turnover | ||
| Latest interim period vs. prior period | Industry | Market |
|---|---|---|
|
|
|
|
|
|
|
| 3yr Compound Annual Growth Rate | Industry | Market |
|---|---|---|
|
|
|
|
|
|
|
|
|
|
|
Revenue
Net Income
Normalised EPS
PE Ratio Range
Dividend Yield Range
|
Price Target:
( below Price)
|
31st Dec 2021
|
31st Dec 2022
|
||||
|---|---|---|---|---|---|---|
| Est. Long Term Growth Rate: |
Net Profit () |
EPS () |
DPS () |
Net Profit () |
EPS () |
DPS () |
| Consensus Estimate | ||||||
| 1m Change | ||||||
| 3m Change | ||||||
Illumina, Inc. (Illumina) is a provider of sequencing- and array-based solutions for genetic analysis. The Company operates through two segments: Core Illumina and the consolidated variable interest entities (VIEs), which include the activities of GRAIL, Inc. (GRAIL) and Helix Holdings I, LLC (Helix). Core Illumina consists of its core operations. Core Illumina's products and services serve customers in the research, clinical and applied markets, and enable the adoption of a range of genomic solutions. The Company's portfolio of integrated systems, consumables and analysis tools addresses the range of genomic complexity, price points, and throughput, enabling customers to select the solution for their research or clinical challenge. The Company provides reproductive-health solutions, including noninvasive prenatal testing (NIPT), preimplantation genetic screening and diagnosis, and neonatal and genetic health testing.
| Last Annual | January 3rd, 2021 |
| Last Interim | January 3rd, 2021 |
| Incorporated | May 16, 2000 |
| Public Since | July 28, 2000 |
| No. of Shareholders: | 126 |
| No. of Employees: | 7,800 |
| Sector | Healthcare |
| Industry | Healthcare Equipment & Supplies |
| Index | Nasdaq Composite , Nasdaq 100 , S&P Composite 1500 , S&P 500 , S&P 500 Health Care (sector), |
| Exchange | NASDAQ Global Select Market |
| Shares in Issue | 145,900,000 |
| Free Float | (0.0%) |
| Eligible for |
ISAs
SIPPs
|
| Address | 5200 Illumina Way, SAN DIEGO, 92122-4616, United States |
| Web | https://www.illumina.com |
| Phone | +1 858 2024500 |
| Contact | Jacquie Ross (Vice President, Investor Relations) |
| Auditors | Ernst & Young LLP |
As of 02/03/21, shares in Illumina Inc are trading at $441.01, giving the company a market capitalisation of £46.79bn. This share price information is delayed by 15 minutes.
Shares in Illumina Inc are currently trading at $441.01 and the price has moved by 68.07% over the past 365 days. In terms of relative price strength - which takes into account the overall market trend - the Illumina Inc price has moved by 36.27% over the past year.
Of the analysts with advisory recommendations for Illumina Inc, there are there are currently 3 "buy" , 8 "hold" and 0 "sell" recommendations. The overall consensus recommendation for Illumina Inc is Hold. You can view the full broker recommendation list by unlocking its StockReport.
Illumina Inc is scheduled to issue upcoming financial results on the following dates:
Illumina Inc does not currently pay a dividend.
Illumina Inc does not currently pay a dividend.
Illumina Inc does not currently pay a dividend.
To buy shares in Illumina Inc you'll need a share-dealing account with an online or offline stock broker. Once you have opened your account and transferred funds into it, you'll be able to search and select shares to buy and sell. You can use Stockopedia’s share research software to help you find the the kinds of shares that suit your investment strategy and objectives.
Shares in Illumina Inc are currently trading at $441.01, giving the company a market capitalisation of £46.79bn.
Here are the trading details for Illumina Inc:
Based on an overall assessment of its quality, value and momentum, Illumina Inc is currently classified as a High Flyer. The classification is based on a composite score that examines a wide range of fundamental and technical measures. Stock are classified on the the following spectrum: Super Stocks, High Flyers, Contrarians, Turnarounds, Neutral, Value Traps, Momentum Traps, Falling Stars, and Sucker Stocks. For more information, learn about our StockRank Styles.
Shares in Illumina Inc are currently priced at $441.01. At that level they are trading at 25.1% premium to the analyst consensus target price of 0.00.
Analysts covering Illumina Inc currently have a consensus Earnings Per Share (EPS) forecast of 6.114 for the next financial year.
An important predictor of whether a stock price will go up is its track record of momentum. Price trends tend to persist, so it's worth looking at them when it comes to a share like Illumina Inc. Over the past six months, the relative strength of its shares against the market has been 11.04%. At the current price of $441.01, shares in Illumina Inc are trading at 23.98% against their 200 day moving average. You can read more about the power of momentum in assessing share price movements on Stockopedia.
The Illumina Inc PE ratio based on its reported earnings over the past 12 months is 0.101k. The shares are currently trading at $441.01.
The PE ratio (or price-to-earnings ratio) is the one of the most popular valuation measures used by stock market investors. It is calculated by dividing a company's price per share by its earnings per share.
The PE ratio can be seen as being expressed in years, in the sense that it shows the number of years of earnings which would be required to pay back the purchase price, ignoring inflation. So in general terms, the higher the PE, the more expensive the stock is.
Illumina Inc's management team is headed by:
Here are the top five shareholders of Illumina Inc based on the size of their shareholding:
